Induced pluripotent stem cells (iPSCs) represent a transformative platform for regenerative medicine and cell therapy, but clinical success depends on safe and reliable reprogramming methods. This study reports the first…
Read More
Touchlight’s dbDNA (doggybone DNA) is a novel and disruptive advancement in DNA manufacturing technology, designed to overcome the limitations of traditional plasmid DNA (pDNA) production. Download the poster here: 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
Read More
Within advanced therapy manufacturing, more and more companies are turning to enzymatically produced DNA as an alternative to plasmid DNA.
Read More
As advanced therapies continue to transform the healthcare landscape, the need for sustainable manufacturing solutions grows more critical. Traditional plasmid DNA (pDNA) production presents costly, resource-intensive challenges, threatening scalability and…
Read More
Rewriting the Rules of Gene Therapy with Nonviral DNA Delivery Published: 14 November 2024 Lisa Caproni, Ph.D. As gene therapy continues to evolve, nonviral DNA delivery is rapidly gaining traction…
Read More
ELENA STOYANOVA, PH.D. & TOM ADIE, PH.D. Touchlight is at the forefront of innovation in gene editing technology with our groundbreaking MegaBulb DNA (mbDNA). This novel, circular, single-stranded DNA template…
Read More
Touchlight is pioneering the next generation of DNA manufacturing with our transformative dbDNA™ technology. The enzymatic DNA manufacturing platform sets new industry standards for speed, purity, and scalability, overcoming the…
Read More
TOM MERRITT, PH.D. Traditional methods for the production of adeno-associated viral (AAV) vectors — crucial components in gene therapies — rely on plasmid DNA (pDNA), which can pose safety concerns…
Read More
Elena Stoyanova, Hyatt Balke-Want, Marianna Romito, Debra Barberini In this virtual seminar, cell engineering scientists from Stanford University, Touchlight Genetics, and MaxCyte share promising advances in non-viral gene therapy. Join…
Read More
Download the poster here
Read More
